CORRIGENDUM to ‘Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis’

Background The approval of monoclonal antibodies for prevention of migraine has revolutionized treatment for patients. Oral preventatives are still considered first line treatments as head-to-head trials comparing them with antibodies are lacking. Methods The main purpose of this study was to provide a comparative overview of the efficacy of three commonly prescribed migraine preventative medication classes. For this systematic review and meta-analysis, we searched the databases CENTRAL, EMBASE, and MEDLINE until 20 March 2020. We included RCTs reporting the 50% response rates for topiramate, Botulinum Toxin Type A and monoclonal antibodies against CGRP(r). Studies were excluded if response rates were not reported, treatment allocation was unclear, or if study quality was insufficient. Primary outcome measure were the 50% response rates. The pooled odds ratios with 95% confidence intervals were calculated with the random effects model. The study was registered at PROSPERO (CRD42020222880). Findings We identified 6552 reports. Thirty-two were eligible for our review. Studies assessing monoclonal antibodies included 13,302 patients and yielded pooled odds ratios for the 50% response rate of 2.30 (CI: 2.11–2.50). Topiramate had an overall effect estimate of 2.70 (CI: 1.97–3.69) with 1989 included patients and Botulinum Toxin Type A achieved 1.28 (CI: 0.98–1. 67) with 2472 patients included. Interpretation Topiramate, botulinum toxin type A and monoclonal antibodies showed higher odds ratios in achieving a 50% response rate compared to placebo. Topiramate numerically demonstrated the greatest effect size but also the highest drop-out rate.

Download Full-text

Calcitonin-Gene-Related Peptide (CGRP) Monoclonal Antibodies in Migraine Prevention; Literature Review

World Journal of Environmental Biosciences ◽

10.51847/ogc7ozojph ◽

2021 ◽

Vol 10 (1) ◽

pp. 48-51

Author(s):

Haneen Ahmed Khouja ◽

Rawan Awadh Alshehri ◽

Hussain Mirza Alhalal ◽

Hassan Dhafer Alabisi ◽

Salhah Mohammad Alajmi ◽

...

Keyword(s):

Monoclonal Antibodies ◽

Literature Review ◽

Calcitonin Gene Related Peptide ◽

Migraine Prevention ◽

Related Peptide ◽

Calcitonin Gene

Download Full-text

Faculty Opinions recommendation of Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.740841829.793589283 ◽

2021 ◽

Author(s):

Sarah Wise

Keyword(s):

Systematic Review ◽

Monoclonal Antibodies ◽

Chronic Rhinosinusitis ◽

Nasal Polyposis ◽

Meta Analysis ◽

Efficacy And Safety ◽

Comparative Efficacy ◽

Aspirin Desensitization

Download Full-text

Passive-specific immunotherapy with monoclonal antibodies for prostate cancer: A systematic review

Journal of Oncology Pharmacy Practice ◽

10.1177/1078155218808080 ◽

2018 ◽

Vol 25 (4) ◽

pp. 903-917 ◽

Cited By ~ 1

Author(s):

Neda Khalili ◽

Mahsa Keshavarz-Fathi ◽

Sepideh Shahkarami ◽

Armin Hirbod-Mobarakeh ◽

Nima Rezaei

Keyword(s):

Prostate Cancer ◽

Systematic Review ◽

Monoclonal Antibodies ◽

Advanced Prostate Cancer ◽

Search Strategy ◽

Specific Immunotherapy ◽

Therapeutic Option ◽

Grey Literature ◽

Statistical Heterogeneity ◽

Specific Antigens

Introduction Treatment of metastatic castration-resistant prostate cancer with conventional therapies is still not successful. Therefore, application of novel biological approaches such as immunotherapy, which appears to be more effective and less toxic, is necessary. Monoclonal antibodies against cancer specific antigens are a kind of immunotherapy that have been approved for specific types of cancer and are being investigated for prostate cancer as well. The aim of this review was to assess the effectiveness and safety of monoclonal antibodies for treatment of advanced prostate cancer. Method According to the search strategy stated in our systematic review protocol, Scopus, Medline, TRIP, CENTRAL, ProQuest, DART and OpenGrey databases were searched. Data collection and quality assessment were done independently by two authors and any disagreements between the collected data were resolved by a third author. A meta-analysis was not feasible as there was a considerable statistical heterogeneity among the trials. Hence, this review was limited to a narrative analysis of the included studies. Results We found 9756 references by applying search strategy in 4 databases of journal articles and 3 databases of grey literature. We then discarded 3957 duplicate citations using Endnote software and 5143 articles due to obvious irrelevancy of their topics in primary screening. In secondary screening of 656 fulltexts, we excluded 538 articles, and finally included 12 trials in this systematic review, updated on 23 June 2017. The overall quality of the studies was fair. In general, results of this systematic review show promising advances in the treatment of prostate cancer patients with monoclonal antibodies against prostate-specific antigens with regard to PSA/disease response. Some of the studies reported pain relief after treatment as well. Conclusion Currently, the role of immunotherapy in the treatment of advanced prostate cancer still remains debated. Although passive specific immunotherapy could be offered as a novel therapeutic option in the coming years, patients should be informed about the risks and benefits of this therapy. One of the obstacles in this review was the lack of adequate assessment of survival-related endpoints reported in the included studies. Our study provides support for further research in this field.

Download Full-text